SPTX insider transaction filings
Seaport Therapeutics, Inc. — 15 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-24. Screen SPTX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 1 insider — 13,000 shares, $235,768 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 13,000 shares @ $18.14 ($235,768) by HOMBACH ROBERT J., filed 2026-06-24.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| HOMBACH ROBERT J. — Director | 1 | 1 leg · 13,000 sh · $235,768 | — | — |
Recent Form 4 filings — Seaport Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-24 | 4 | HOMBACH ROBERT J. — Director | Purchase (P): 13,000 @ $18.14 | EDGAR |
| 2026-05-06 | 4 | PureTech Health plc — 10% owner PureTech LYT, Inc. — 10% owner | Conversion (C): 12,736,014 · Conversion (C): 2,681,265 · Conversion (C): 965,255 · Conversion (C): 40,000,000 (derivative) @ $0 · Conversion (C): 8,421,052 (derivative) @ $0 · Conversion (C): 3,031,578 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Gladstein Lana — General Counsel | Conversion (C): 33,515 · Grant/award (A): 63,680 (derivative) @ $0 · Conversion (C): 105,263 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Chen Michael Cunyuan — Chief Scientific Officer | Conversion (C): 3,351 · Grant/award (A): 63,680 (derivative) @ $0 · Conversion (C): 10,526 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | White Lauren — Chief Financial Officer | Conversion (C): 6,702 · Grant/award (A): 63,680 (derivative) @ $0 · Conversion (C): 21,052 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Torres Denice — Director | Conversion (C): 13,406 · Grant/award (A): 12,258 (derivative) @ $0 · Conversion (C): 42,105 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Loebel Antony — Chief Medical Officer | Conversion (C): 20,109 · Grant/award (A): 63,680 (derivative) @ $0 · Conversion (C): 63,157 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Wheadon David E. — Director | Grant/award (A): 12,258 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Zohar Daphne — Chief Executive Officer, Director | Grant/award (A): 271,813 (derivative) @ $0 · Grant/award (A): 1,486,786 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Mates Sharon — Director | Grant/award (A): 49,033 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | HOMBACH ROBERT J. — Director | Grant/award (A): 12,258 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | HEALY JAMES — Director | Conversion (C): 1,927,159 · Conversion (C): 804,379 · Conversion (C): 6,052,631 (derivative) @ $0 · Conversion (C): 2,526,315 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | PAUL STEVEN M — Director | Conversion (C): 67,031 · Grant/award (A): 12,258 (derivative) @ $0 · Grant/award (A): 991,192 (derivative) @ $0 · Conversion (C): 210,526 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | ARCH Venture Partners XII, LLC — 10% owner ARCH Venture Partners XII, L.P. — 10% owner ARCH Venture Fund XII, L.P. — 10% owner CRANDELL KEITH — 10% owner NELSEN ROBERT — 10% owner Burow Kristina — 10% owner GILLIS STEVEN — 10% owner | Conversion (C): 2,513,686 · Conversion (C): 2,681,265 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 2,513,686 (derivative) @ $0 · Conversion (C): 2,681,265 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | PETERSON SANDRA E — Director | Grant/award (A): 12,258 (derivative) @ $0 | EDGAR |
Recent 8-K events — Seaport Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SPTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →